Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Open Label Multicenter Trial to Investigate the Efficacy of a Treat-to-target (T2T) Treatment Strategy With Secukinumab (AIN457) as a First-line Biologic Compared to a Standard-of-care (SOC) Treatment Over 36 Weeks in Patients With Active Axial Spondyloarthritis (axSpA)

Next Previous
Trial Profile

A Randomized, Open Label Multicenter Trial to Investigate the Efficacy of a Treat-to-target (T2T) Treatment Strategy With Secukinumab (AIN457) as a First-line Biologic Compared to a Standard-of-care (SOC) Treatment Over 36 Weeks in Patients With Active Axial Spondyloarthritis (axSpA)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 21 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Secukinumab (Primary) ; Adalimumab
  • Indications Ankylosing spondylitis; Axial spondyloarthritis; Non-radiographic axial spondyloarthritis; Spondylarthritis
  • Focus Registrational; Therapeutic Use
  • Acronyms AScalate
  • Sponsors Novartis Pharmaceuticals

Most Recent Events

  • 15 Jun 2024 According to Results presented at the 25th Annual Congress of the European League Against Rheumatism Primary endpoint (Percentage of patients achieving an Assessment of responders for the SpondyloArthritis International Society (ASAS) 40 response) has not been met.
  • 15 Jun 2024 Results assessing efficacy of Secukinumab Versus Standard-of-Care in Axial Spondyloarthritis presented at the 25th Annual Congress of the European League Against Rheumatism
  • 05 Jan 2023 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top